Fellow - Radiation Oncology Fellow - Radiation Oncology

Unique opportunity to spend 2 years in 2 leading #radonc centres Come and join us & research @mcrcnews.bsky.social @petermaccc.bsky.social @estroradiotherapy.bsky.social @astro-org.bsky.social @rcradiologists.bsky.social #WhereisHoskin
Closing 07/04/26
careers.petermac.org/job/MELBOURN...

#WhereisHoskin champions #SBRT for the debate win! It's compelling to think that precise treatment with minimal side-effects can cure. Now we need randomised robust data #RENALC25 @oncoalert.bsky.social @mcrcnews.bsky.social

It's Manchester v Manchester in the #GoGreenESTRO debate #WhereisHoskin explains that global data & virtual meetings have a significant carbon footprint - our data appetite is carbonivorous. F2F has plenty of benefits🤔 @mcrcnews.bsky.social @uniofmanchester.bsky.social @robchuter.bsky.social

#WhereisHoskin describes the #radiobiology of brachytherapy. It's complex, so for a bit of light relief - we have a quiz Q - answer 1954!
#ESTRO25 @mcrcnews.bsky.social @uniofmanchester.bsky.social

Podcast: Practice-Informing Research Across GU Oncology: Highlights From GU25 Dr. Neeraj Agarwal and Dr. Peter Hoskin discuss key abstracts in GU cancers from the 2025 ASCO Genitourinary Cancers Symposium, including novel therapies in prostate, bladder, and kidney cancer and th...

Dr Neeraj Agarwal of @huntsmancancer.bsky.social and #WhereisHoskin @officialuom.bsky.social @mcrcnews.bsky.social recap key studies from #GU25 + highlight research on prostate, bladder, and kidney cancer on the latest episode of the #ASCODailyNews Podcast: brnw.ch/21wR4ZB

The Promise of Radiotherapy in High-Risk Non-Muscle Invasive Bladder Cancer Global shortages, toxicities, and high levels of incomplete treatment with Bacillus Calmette Guerin (BCG) for non-muscle invasive bladder cancer has resulted in increasing interest in alternative trea...

Our review on the promise of #radiotherapy in #NMIBC #Openaccess #WhereisHoskin @mcrcnews.bsky.social @oncoalert.bsky.social @southamptonctu.bsky.social #TRAINTrial
www.mdpi.com/2072-6694/17...

It's the #COAC Clinical Oncology Academic Study Day
#WhereisHoskin gives the dos & don'ts of publishing
Take home message: no case reports! @mcrcnews.bsky.social #RCR @oncoalert.bsky.social

#WhereisHoskin guides us through the evidence for salvage #radiotherapy for #prostatecancer Some things are clear
➡️ Early salvage
➡️ No benefit of dose escalation
Others not
➡️ Duration of ADT
➡️ Impact of nodal RT
@oncoalert.bsky.social #PROSCA24

I was on the same table as #WhereIsHoskin at a National Cancer Programme event in London three weeks ago. 😊👍🏻

#WhereisHoskin appears on #BlueSky How to further personalise #radiotherapy
➡️ Bladder only unless N+
➡️ Give NAC if appropriate
➡️ Use a radiosensitiser, any radiosensitiser
➡️ There are compelling biomarkers, but need prospective qualification
#BLADDR24 @oncoalert.bsky.social